Review
Oncology
Tresa M. McGranahan, Alipi Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo
Summary: This paper reviews the treatment options for patients with HER2+ breast cancer brain metastasis and provides a simplified algorithm for when to consider delaying local treatments.
Review
Oncology
Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Summary: HR-positive/HER2-negative breast cancer is characterized by the presence of estrogen receptor and/or progesterone receptor and the absence of HER2 gene amplification. It accounts for a significant proportion of breast cancers and is treated with endocrine therapy. Combining endocrine therapy with cyclin-dependent kinase inhibitors has shown promising results in reducing recurrence and improving survival. Chemotherapy is used based on the stage and tumor biology. New therapies, such as novel endocrine agents and antibody-drug conjugates, are changing the treatment landscape.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Oncology
Anastasia Alataki, Mitch Dowsett
Summary: Endocrine therapies are the main treatment for hormone-dependent breast cancer, but HER2 signaling contributes to resistance and affects treatment efficacy. HER2 overexpression plays a role in resistance to endocrine therapies in breast cancer patients, impacting their clinical outcomes.
ENDOCRINE-RELATED CANCER
(2022)
Article
Oncology
Tianyu Zeng, Hai Xu, Yincheng Liu, Chunxiao Sun, Fan Yang, Yan Liang, Xiang Huang, Ziyi Fu, Wei Li, Yongmei Yin
Summary: This study assessed the frequency of lung cancer following breast cancer diagnosis and the associations between the two types of cancer. The results showed that breast cancer patients, especially those with low-grade malignancy, have a higher risk of developing primary lung cancer. Close follow-up is recommended for patients with isolated ground-glass nodules and high-risk factors. Additionally, EGFR may play an important role in primary lung adenocarcinomas and breast cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ivica Ratosa, Nika Dobnikar, Michele Bottosso, Maria Vittoria Dieci, William Jacot, Stephane Pouderoux, Domen Ribnikar, Lea Sinoquet, Valentina Guarneri, Tanja Znidaric, Amelie Darlix, Gaia Griguolo
Summary: Leptomeningeal metastases (LM) in patients with HER2+ breast cancer are rare but often fatal. This multicentric study retrospectively gathered data from 82 patients with advanced HER2+ breast cancer and LM. The study found that absence of neurological symptoms and receiving radiotherapy were associated with prolonged overall survival.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Preeti Narayan, Asma Dilawari, Christy Osgood, Zhou Feng, Erik Bloomquist, William F. Pierce, Samina Jafri, Shyam Kalavar, Marina Kondratovich, Prakash Jha, Soma Ghosh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: The US FDA approved fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer. This is the first approved therapy specifically for HER2-low metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Volkmar Mueller, Rupert Bartsch, Nancy U. Lin, Filippo Montemurro, Mark D. Pegram, Sara M. Tolaney
Summary: This systematic literature review provides a comprehensive overview of the epidemiology, unmet needs, and treatment landscape for patients with HER2+ metastatic breast cancer and brain metastases. There is a need for standardization of clinical trial design to ensure all types of brain metastases can access effective treatments.
CANCER TREATMENT REVIEWS
(2023)
Review
Oncology
Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan, Xiaoming Xie
Summary: This article provides an overview of the therapeutic landscape of HER2+BC by reviewing research results and introducing the latest evidence, aiming to provide a reference for clinical treatment.
Review
Oncology
Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang
Summary: HR+/HER2+ metastatic breast cancer is a unique subtype of breast cancer. Combination regimens and endocrine therapy can provide long-term disease control, but accurately identifying the subset of patients who can benefit from de-chemotherapy treatment strategy is challenging.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Gulijire Tailaiti, Gulanbaier Maimaiti, Youlituzi Aikeremu, Batuer Tuerdi
Summary: Molybdenum target X-ray mammography features are correlated with the expressions of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 in invasive breast cancer. The expressions of ER and PR are positively correlated with the absence of axillary lymph node enlargement and negatively correlated with the maximum tumor diameter.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2021)
Article
Oncology
Huimin Lv, Min Yan, Zefei Jiang
Summary: HR+/HER2+ advanced breast cancer is often treated with a combination of anti-HER2 therapy as the first-line treatment, with endocrine therapy reserved for patients who cannot tolerate chemotherapy. Previous studies have shown that combined therapy targeting both the HR and HER2 pathways can effectively prevent tumor resistance.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu
Summary: This study investigated the short-term clinical efficacy of neoadjuvant therapies trastuzumab and trastuzumab+pertuzumab for early HER2-positive breast cancer patients in China. It was found that patients in the trastuzumab+pertuzumab group had a higher pCR rate with tolerable toxic side effects compared to those in the trastuzumab group.
CHINESE MEDICAL JOURNAL
(2022)
Article
Oncology
Lei Lei, Han-Ching Chan, Tzu-Pin Lu, Skye Hung-Chun Cheng
Summary: The prognosis of low-risk patients classified according to the Dutch criteria is excellent regardless of whether they receive adjuvant chemotherapy. In contrast, high-risk patients have significantly poorer breast cancer-specific survival and overall survival, suggesting that these patients may benefit from multi-gene testing.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Rita Saude-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz, Francesco Sclafani
Summary: This article summarises the current knowledge about HER2 alterations in CRC and the potential of anti-HER2 therapies. Recent studies confirm the therapeutic potential of established and new anti-HER2 agents, as well as the utility of liquid biopsy and ctDNA analyses for HER2 detection. HER2 represents a valuable target for emerging anti-HER2 therapies.
CURRENT OPINION IN ONCOLOGY
(2022)
Article
Oncology
Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto
Summary: This study aimed to determine the incidence and clinical course of histologic transformation (HT) in lung cancer patients with epidermal growth factor receptor (EGFR) mutations. The study found that approximately 3% of EGFR-mutated patients developed HT after acquiring resistance to EGFR-tyrosine kinase inhibitors (TKIs). There was no significant difference in survival between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Cytotoxic agents were likely to be effective in patients with HT, while the effectiveness of immune checkpoint inhibitors was limited.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Zisun Kim, Sun Young Min, Chan Seok Yoon, Kyu-Won Jung, Beom Seok Ko, Eunyoung Kang, Seok Jin Nam, Seolcwon Lee, Min Hee Hur
JOURNAL OF BREAST CANCER
(2015)
Article
Cell Biology
Ju-Hyun Shin, Kwang Sik Chun, Yong-Gil Na, Ki-Hak Song, Seung Il Kim, Jae-Sung Lim, Gun-Hwa Kim
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
(2015)
Article
Oncology
Kyung Ha Lee, Myung Sun Lee, Eun Young Cha, Ji Young Sul, Jin Sun Lee, Jin Su Kim, Jun Beom Park, Ji Yeon Kim
MOLECULAR MEDICINE REPORTS
(2017)
Article
Multidisciplinary Sciences
So Yeon Kim, Jong-Min Jeong, Soo Jin Kim, Wonhyo Seo, Myung-Ho Kim, Won-Mook Choi, Wonbeak Yoo, Jun-Hee Lee, Young-Ri Shim, Hyon-Seung Yi, Young-Sun Lee, Hyuk Soo Eun, Byung Seok Lee, Kwangsik Chun, Suk-Jo Kang, Sun Chang Kim, Bin Gao, George Kunos, Ho Min Kim, Won-Il Jeong
NATURE COMMUNICATIONS
(2017)
Article
Oncology
Jun Beom Park, Jin Sun Lee, Myung Sun Lee, Eun Young Cha, Soyeon Kim, Ji Young Sul
MOLECULAR MEDICINE REPORTS
(2018)
Article
Gastroenterology & Hepatology
Hyuk Soo Eun, Sang Yeon Cho, Byung Seok Lee, Sup Kim, In-Sang Song, Kwangsik Chun, Cheong-Hae Oh, Min-Kyung Yeo, Seok Hyun Kim, Kyung-Hee Kim
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2019)
Article
Oncology
Jin Sun Lee, Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Ji Young Sul, Jun Beom Park, Young Bok Ko
MOLECULAR MEDICINE REPORTS
(2018)
Article
Oncology
Younju Lee, Jinuk Na, Myung Sun Lee, Eun Young Cha, Ji Young Sul, Jun Beom Park, Jin Sun Lee
MOLECULAR MEDICINE REPORTS
(2018)
Article
Medicine, Research & Experimental
Chang Eun Jang, Mi Sook Jung, Eun Hee Sohn, Mijung Kim, Hwa-Seung Yoo, Kyeore Bae, Je Ryong Kim, Jin Sun Lee
Article
Medicine, Research & Experimental
Jin Sun Lee, Ji Young Sul, Jun Beom Park, Myung Sun Lee, Eun Young Cha, Young Bok Ko
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2019)
Article
Cell Biology
Hyon-Seung Yi, So Yeon Kim, Jung Tae Kim, Young-Sun Lee, Ji Sun Moon, Mingyo Kim, Yea Eun Kang, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Kwangsik Chun, Minho Shong, Bon Jeong Ku
CELL DEATH & DISEASE
(2019)
Article
Chemistry, Analytical
Hong Ngoc Pham, Chieu An Tran, Thi Diep Trinh, Ngoc Lan Nguyen Thi, Huynh NhuTran Phan, Van Nhan Le, Ngoc Hung Le, Van Trung Phung
Summary: This research analyzed and evaluated the phytochemical profile of Hedera helix grown in central Vietnam using ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. A total of 46 compounds, including 24 triterpene saponins, were successfully identified, and four previously unreported saponin structures were discovered. This study provides a foundation for quality control and assessment of pharmaceutical ingredients in H. helix planted in Vietnam.
JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY
(2022)
Article
Chemistry, Applied
Diep Trinh Thi, Dung Luong Van, Trung Phung Van, Hoai Nguyen Thi, Thao Do Thi, Uyen Nguyen Thi To, Linh Tran Thi Hoai, Khai Dang Vinh, Thanh Truc Huynh, Tran Le Thi Thanh
Summary: New essential oils (EOs) extracted from different parts of two Luvunga species (L. scandens and L. hongiaoensis) from Vietnam were examined for their chemical composition, anti-inflammatory and cytotoxic activity. The EOs contained various compounds, with beta-caryophyllene being the major constituent in L. scandens, and beta-elemene and caryophyllene oxide being dominant in L. hongiaoensis. The EOs showed anti-inflammatory and cytotoxic effects against certain cells.
NATURAL PRODUCT RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Hyuk Soo Eun, Byung Seok Lee, In Sun Kwon, Gee Young Yun, Eaum Seok Lee, Jong Seok Joo, Jae Kyu Sung, Hee Seok Moon, Sun Hyung Kang, Ju Seok Kim, Hae Jin Shin, Tae Kyun Kim, Kwangsik Chun, Seok Hyun Kim
DIGESTIVE DISEASES AND SCIENCES
(2017)
Article
Oncology
Bo Bae Choi, Jin Sun Lee, Kun Ho Kim
ONCOLOGY RESEARCH AND TREATMENT
(2018)